SCHEMBL474237

SCHEMBL474237

CCc1oc(N)nc1-c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.58
PTGS1 P23219 1/20 0.49
PTGS2 P35354 1/20 0.49
ALDH1A1 P00352 4/20 0.47
MAPT P10636 1/20 0.47
FBP1 P09467 5/20 0.42
KDM4E B2RXH2 3/20 0.40
HPGD P15428 2/20 0.40
DHFR P00374 1/20 0.40
HEXA P06865 1/20 0.40
HEXB P07686 1/20 0.40
LMNA P02545 1/20 0.40
GLA P06280 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NUDT1 P36639 1/20 0.40
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
NOTUM Q6P988 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25350087 0.86 NR4A2 (0.54) NR4A2PTGS1PTGS2ALDH1A1MAPT
SCHEMBL10264165 0.80 MAPK13 (0.51) NR4A2PTGS1PTGS2ALDH1A1MAPT
SCHEMBL2609428 0.79 PTGS1 (0.46) NR4A2PTGS1PTGS2ALDH1A1MAPT
SCHEMBL5214988 0.76 KDM4E (0.66) NR4A2PTGS1PTGS2ALDH1A1MAPT
SCHEMBL5154427 0.75 NR4A2 (0.68) NR4A2ALDH1A1MAPTFBP1KDM4E
SCHEMBL330227 0.73 NR4A2 (1.00) NR4A2PTGS1PTGS2ALDH1A1FBP1
SCHEMBL5154448 0.72 NR4A2 (0.63) NR4A2ALDH1A1MAPTFBP1KDM4E
SCHEMBL9827689 0.72 RAB9A (0.48) ALDH1A1MAPTKDM4EHPGDDHFR
SCHEMBL12088074 0.71 PTGS2 (0.67) NR4A2PTGS1PTGS2ALDH1A1MAPT
SCHEMBL5008393 0.68 MAPK13 (0.50) NR4A2PTGS1PTGS2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1653952-A4 OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PROD INC (US) 2007-04-04 EP claimed
US-7112599-B2 Oxazole compounds for the treatment of neurodegenerative disorders PFIZER INC. (US) 2006-09-26 US claimed
EP-1653952-A2 OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2006-05-10 EP claimed
WO-2005016267-A2 OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2005-02-24 WO claimed
US-20050032859-A1 Oxazole compounds for the treatment of neurodegenerative disorders PFIZER INC. (US) 2005-02-10 US claimed
US-3933498-A Fogged, direct positive silver halide emulsions containing a bleach inhibiting compound and a Dmin maintainer compound E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-01-20 US claimed
EP-2112206-B1 Polymer Composition ROHM & HAAS (US) 2016-06-29 EP disclosed
EP-2166043-B1 Thickener composition and method for thickening aqueous systems ROHM & HAAS (US) 2016-04-27 EP disclosed
EP-2166044-B1 Thickened compositions and method for thickening aqueous polymer compositions ROHM & HAAS (US) 2012-02-01 EP disclosed
US-20110281980-A1 Thickener composition and method for thickening aqueous systems BOBSEIN BARRETT RICHARD (US) 2011-11-17 US disclosed
US-8034869-B2 Thickened compositions and method for thickening aqueous polymer compositions ROHM AND HAAS COMPANY (US) 2011-10-11 US disclosed
US-7985795-B2 Thickener composition and method for thickening aqueous systems ROHM AND HAAS COMPANY (US) 2011-07-26 US disclosed
EP-1972665-B1 Thickener composition and method for thickening aqueous systems ROHM & HAAS (US) 2011-04-27 EP disclosed
EP-1972665-A2 Thickener composition and method for thickening aqueous systems Rohm and Haas Company (US) 2008-09-24 EP disclosed
EP-1653952-A4 OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PROD INC (US) 2007-04-04 EP disclosed
US-7112599-B2 Oxazole compounds for the treatment of neurodegenerative disorders PFIZER INC. (US) 2006-09-26 US disclosed
EP-1653952-A2 OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2006-05-10 EP disclosed
WO-2005016267-A2 OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2005-02-24 WO disclosed
US-20050032859-A1 Oxazole compounds for the treatment of neurodegenerative disorders PFIZER INC. (US) 2005-02-10 US disclosed
US-3933498-A Fogged, direct positive silver halide emulsions containing a bleach inhibiting compound and a Dmin maintainer compound E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032859-A1 Oxazole compounds for the treatment of neurodegenerative disorders APP, OXA1L, BACE1 NR4A2 668/4885PTGS1 3381/4885PTGS2 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.